Autopsy report · NCT03020121

Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples

“Lower than anticipated rate of subject enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 6 months before it stopped.
• 28 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Becton, Dickinson and Company

Sponsor type

Industry

Conditions

Uterine Cervical Neoplasm

Interventions

Colposcopy/biopsy

Participants

28

Sites

12

Countries

Canada, United States

Trials that died the same way

• Development of a NIPTT for Detecting Copy Number Variations
  “Poor rate of eligible subject enrollment” (87% match in meaning)
• Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1
  “Low rate of enrollment” (85% match in meaning)
• Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.
  “Low enrollment rate” (85% match in meaning)
• Miromatrix Biological Mesh for Ventral Hernia Repair
  “enrollment rate” (81% match in meaning)
• Impact of Holotropic Breathwork on Nursing Student Mental Health
  “enrollment lower than expected” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.